Case Report: Treatment of an unresectable mucoepidermoid carcinoma with osimertinib - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Case Study: Osimertinib as a Therapeutic Approach for Unresectable Mucoepidermoid Carcinoma

  • By

  • Leonardo Villa

  • Alice Soares

  • Viviane Basílio

  • Haonne Abboud

  • Daniel Herchenhorn

  • September 11, 2026

Share

  • 1

    Mucoepidermoid carcinoma (MEC) is the most common malignant neoplasm of salivary glands, comprising 10-15% of all salivary gland neoplasms.

  • 2

    Unresectable MEC lacks an established systemic treatment standard, and conventional chemotherapy has low response rates.

  • 3

    Osimertinib, a third-generation EGFR-TKI, was administered to a 72-year-old man with unresectable low-grade MEC, resulting in a 33% tumor reduction.

  • 4

    The patient experienced approximately 13 months of continuous treatment with osimertinib, achieving a partial response and improved symptoms.

  • 5

    This case represents the first reported partial response of oral MEC to a third-generation EGFR-TKI, highlighting the potential for targeted therapy.

Original Source(s)

Case Report: Treatment of an unresectable mucoepidermoid carcinoma with osimertinib

  • by Leonardo Villa, Alice Soares, Viviane Basílio, Haonne Abboud, Daniel Herchenhorn

  • September 11, 2026

Related Content

Correction: Case Report: Complete response and prolonged survival to alectinib in a NSCLC patient with metastases harboring a rare WDR43::ALK structural deletion

Retraction Note: TWIST1 activates cancer stem cell marker genes to promote epithelial‑mesenchymal transition and tumorigenesis in esophageal squamous cell carcinoma

Cost-Effectiveness of Electronic Patient-Reported Outcome Measure Interventions in Cancer: Systematic Review and Parameter Extraction for Economic Modeling